Samjin studying anti-cancer drug development, SJ-8002.

Published: 2004-08-25 06:56:00

Updated: 2004-08-25 06:56:00

Samjin announced that SJ-8002, an anti-cancer drug of piperazine derivative, was successfully developed having an anti-cancer mode of actions by blocking the microtubule generation, angiogenesis and inducement of tumor cell's apoptosis, which was published in the Aug. edition of International Journal of Oncology.

The R&D for SJ-8002 was proceeded jointly with the molecular biology departme...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.